Riskpilot← Back to searchSign inGet full accessORIFARM SUPPLY A/S
A/SActiveCVR 17153684Energivej 15Wholesale of pharmaceutical and medical goods · NACE 4646Est. 1993192 employees
Revenue 2024
DKK 10,5B
+20% vs 2023
EBITDA margin
4.2%
+15% vs 2023
Equity ratio
43.9%
Financial strength
Net profit 2024
DKK 269,4M
+24% vs 2023
| Revenue | DKK 10,5B | +20% |
| EBITDA | DKK 439,4M | +15% |
| Net profit | DKK 269,4M | +24% |
| Total assets | DKK 2,7B | -29% |
| Equity | DKK 1,2B | +30% |
| Employees | 192 | — |
Legal name
ORIFARM SUPPLY A/S
CVR number
17153684
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. juli 1993
Share capital
DKK 10.000.000
Employees
192 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør og et bestyrelsesmedlem eller af to bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er indkøbe, produktion, ompakning og distribution af lægemidler og lignende produkter i Europa
Address
Energivej 15
Phone
+4563952600
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7.025.289 | 8.027.258 | 8.222.801 | 8.746.302 | 10.456.149 |
| Staff expenses | -63.268 | -110.199 | -108.135 | -110.784 | -141.810 |
| EBITDA | 238.398 | 232.278 | 241.726 | 383.632 | 439.366 |
| Depreciation & amort. | -5.316 | -3.801 | -7.110 | -8.027 | -7.812 |
| EBIT | 233.082 | 228.477 | 234.616 | 375.605 | 431.554 |
| Net financials | -4.256 | -5.919 | -36.748 | -96.752 | -73.601 |
| Profit before tax | 228.826 | 222.558 | 197.868 | 278.853 | 357.953 |
| Tax | 55.370 | 48.973 | 43.710 | 61.356 | 88.555 |
| Net profit | 173.456 | 173.585 | 154.158 | 217.497 | 269.398 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1.340.870 | 1.306.291 | 2.709.702 | 3.797.096 | 2.682.167 |
| Equity | 546.723 | 711.955 | 691.113 | 908.610 | 1.178.008 |
| Long-term debt | 5.992 | 0 | 0 | 0 | 0 |
| Short-term debt | 780.292 | 584.445 | 2.006.187 | 2.874.968 | 1.487.986 |
| Total debt | 786.284 | 584.445 | 2.006.187 | 2.874.968 | 1.487.986 |
EBITDA margin
4.2%
This company
15.8%
Market median
-73% vs market
20202024
Equity ratio
43.9%
This company
38.2%
Market median
+15% vs market
20202024
Return on equity
22.9%
This company
18.4%
Market median
+24% vs market
20202024
Net profit margin
2.6%
This company
8.1%
Market median
-68% vs market
20202024
Asset turnover
3.90×
This company
1.12×
Market median
+248% vs market
20202024
Debt / equity
1.28×
This company
0.62×
Market median
-106% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MF Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (5) | ||
US Management | Management | 1993 – 1994 |
ET | Audit | 1993 – 1994 |
ES Chief Executive Officer | Chief Executive Officer | 2014 – 2025 |
RB Chief Executive Officer | Chief Executive Officer | 2005 – 2006 |
JM Management | Management | 2005 – 2007 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2006 | |
| Board of Directors | 2014 | |
| Chairman | 2005 | |
| Board of Directors | 2025 | |
| Former (4) | ||
| Board of Directors | 2005 – 2008 | |
| Board of Directors | 2008 – 2012 | |
| Board of Directors | 2012 – 2014 | |
| Board of Directors | 1993 – 1994 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2009 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ORIFARM GROUP A/S
ORIFARM SUPPLY A/S Board members of ORIFARM SUPPLY A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Svejgaard Poulsen | Management | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Mads Fink Eriksen | Chief Executive Officer | 0 companies |
| Erik Sandberg | Chief Executive Officer | 0 companies |
| Ragnhild Birgitte Jensen | Chief Executive Officer | 0 companies |
| John Morell Frellsen | Management | 0 companies |
| Per Munk Laustsen | Board of Directors | 0 companies |
| Hans Carl Bøgh-Sørensen | Board of Directors | 0 companies |
| Ole Ibsen | Board of Directors | 0 companies |
| Birgitte Bøgh-Sørensen | Board of Directors | 0 companies |
| Hans Christian Eberhard Groth Teisen | Board of Directors | 0 companies |
| Ole Michael Friis | Chairman | 0 companies |
| Per Emil Hasselbalch Stakemann | Board of Directors | 0 companies |
| Nicki Lund Kristensen | Board of Directors | 0 companies |